Obesity and Alzheimer's drugs pack one-two punch to power Eli Lilly higher in 2024
After climbing 55% in 2023, Eli Lilly's stock still has room to grow.
JaneWalter
0
105
Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.
George Frey | Bloomberg | Getty Images
Investor optimism for Eli Lilly's diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story.
/cdn.vox-cdn.com/uploads/chorus_asset/file/23630242/acastro_STK052_02.jpg)
/cdn.vox-cdn.com/uploads/chorus_asset/file/25301215/STK463_SCOTUS_B.jpg)
